Search ARM

StemSight is a spin-out from Professor Heli Skottman’s lab in Tampere University, Finland. StemSight develops allogeneic iPS cell-based therapies for corneal blindness. StemSight’s first product is aimed at the rare disease called limbal stem cell deficiency, aiming to restore vision in these severely blinded patients.

Contact StemSight Oy
Visit Website